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Abstract
Background: Accelerated clearance of 99mtechnetium-sestamibi (MIBI) has been observed after reperfusion therapy in
patients with acute coronary syndrome (ACS), but the mechanisms have not been fully investigated. MIBI retention
may depend on mitochondrial function. The clearance rate of 11carbon-acetate reflects such mitochondrial functions as
oxidative metabolism. The purpose of this study was to examine the mechanisms of accelerated MIBI clearance in ACS.
We therefore compared it to oxidative metabolism estimated using 11C-acetate positron emission tomography (PET).
Methods: Eighteen patients [mean age 69.2 ± 8.7 years, 10 males (56 %)] with reperfused ACS underwent MIBI single-
photon emission computed tomography (SPECT), echocardiography, and 11C-acetate PET within 3 weeks of the onset of
ACS. MIBI images were obtained 30 min and 3 h after MIBI administration. Regional left ventricular (LV) function was
evaluated by echocardiography. The measurement of oxidative metabolism was obtained through the mono-exponential
fitting of the 11C-acetate time-activity curve (kmono).
Results: Among 95 segments of reperfused myocardium, MIBI SPECT showed 64 normal segments (group N), 14
segments with accelerated MIBI clearance (group AC), and 17 segments with fixed defect (group F). Group AC showed
lower kmono than group N (0.041 ± 0.009 vs 0.049 ± 0.010, p = 0.02). Group F showed lower kmono than group N (0.039 ±
0.012 vs 0.049 ± 0.010, p = 0.01). However, kmono was similar in group AC and group F (p = 0.99).
Conclusions: Segments with accelerated MIBI clearance showed reduced oxidative metabolism in ACS. Loss of
MIBI retention may be associated with mitochondrial dysfunction.
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Background
Acute coronary syndrome (ACS) induces myocardial is-
chemia followed by myocardial cell injury. ACS-induced
myocardial cell injury may also cause mitochondrial
dysfunction. Myocardial mitochondrial dysfunction is
thought to be associated with the process of myocardial
cell death [1]. Early intervention to protect mitochondrial
function may also be important for myocyte protection
[2]. Therefore, accurate detection of mitochondrial
dysfunction in patients with ACS is considered to be
important.
99mTechnetium-sestamibi (MIBI) is a lipophilic and
cationic agent that is passively taken up by myocytes
after intravenous administration. MIBI is distributed on
the mitochondrial membrane in relation to the electrical
gradient [3, 4]. Accelerated MIBI clearance has been
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observed in patients with acute myocardial infarction
after reperfusion therapy [5], and it may be a predictor
of left ventricular (LV) functional improvement at
follow-up [6].
11C-acetate positron emission tomography (PET) can
non-invasively evaluate myocardial oxidative metabolism
[7–12] and myocardial blood flow [13, 14]. 11C-acetate
clearance is associated with citric acid cycle activity in
the mitochondria, in which acetate is converted into
acetyl-CoA and metabolized via the action of acetyl-CoA
synthetase 2 [15]. Therefore, oxidative metabolism as es-
timated using 11C-acetate PET can be associated with
mitochondrial function. Previous studies have suggested
an association between accelerated MIBI clearance and
mitochondrial dysfunction in dilated and hypertrophic
cardiomyopathy based on experimental researches [16].
However, no previous study has looked at the patho-
physiological mechanisms of accelerated MIBI clearance
in patients with ACS.
The purpose of this study was to examine the mechan-
ism of accelerated MIBI clearance in patients with ACS.
Therefore, we compared it to oxidative metabolism esti-
mated using 11C-acetate PET. The second aim of this
study was to evaluate the association between regional




ACS patients were prospectively recruited from the De-
partment of Cardiovascular Medicine at the Hokkaido
University Hospital from August 2006 to February 2012.
We enrolled patients diagnosed with ACS [17] who had
revascularization immediately after admission to the
hospital [mean age 69.2 ± 8.7 years, 10 males (56 %)].
ACS included unstable angina, non-ST-elevated myocar-
dial infarction (NSTEMI), and ST-elevated myocardial
infarction (STEMI) [18]. Exclusion criteria were (1) pa-
tients with prior myocardial infarction, (2) patients who
were younger than 20 years old, and (3) patients whose
condition was unstable. The study was approved by the
Hokkaido University Graduate School of Medicine Hu-
man Research Ethics Board. Written informed consent
was obtained from all patients.
Study protocol
Within 20 days of the onset of ACS, patients had rest
and delayed rest MIBI single-photon emission computed
tomography (SPECT), rest 11C-acetate PET, and echo-
cardiography at rest. These three imaging data acquisi-
tions were performed within 7 days. The interval
between nuclear imaging and echocardiography was 1.7
± 2.4 days (Fig. 1). Follow-up echocardiography was per-
formed 6 months after the onset of ACS (Fig. 1).
MIBI SPECT myocardial perfusion imaging
MIBI SPECT myocardial perfusion imaging was per-
formed at rest. Six hundred megabecquerels (MBq) of
MIBI (FUJIFILM RI Pharma, Tokyo, Japan) was intra-
venously administered at rest. Standard data acquisition
was performed 30 min after MIBI administration [19],
and an additional rest SPECT data acquisition was per-
formed 180 min after MIBI administration [5].
All images were obtained using a dual-detector gamma
camera (Millennium MG, General Electric, Elgems, Tirat
Carmel, Israel) equipped with a parallel hole, low-
energy, high-resolution collimator. Energy discrimin-
ation was provided by a 20 % window centered at
140 keV. Thirty-two images were obtained over a 180°
arc. Each image was acquired over 30 s. The data were
stored on a 64 × 64 matrix. A series of 6.78-mm-thick
contiguous trans-axial images were reconstructed with a
filtered back-projection algorithm without attenuation
correction. These trans-axial images were then reor-
iented in the short axis, vertical long axis, and horizontal
long axis of the left ventricle.
MIBI SPECT image interpretation
The LV wall was divided into 16 segments based on
the American Society of Echocardiography (ASE) rec-
ommendations [20]. Each basal and mid-ventricular
region was divided into six segments, and the apical
region was divided into four segments. The border
between the anteroseptal and anterior segments was
considered to be at the anterior insertion of the right
ventricular wall into the left ventricle. Also, the infer-
ior insertion of the right ventricular wall into the left
ventricle defined the border between the inferoseptal
Enrolled patients (n = 18) 
Initial evaluation (n = 18)
within 20 days of ACS onset
Follow-up UCG evaluation (n = 17)
after 6 months of ACS onset
Lost to follow-up (n = 1) 
Fig. 1 Study protocol. ACS acute coronary syndrome
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and inferior segments [20]. The association between
the myocardial segments and the three major coron-
ary arteries was also defined based on the ASE rec-
ommendations [20]. The left anterior descending
artery (LAD) region included six segments, the left
circumflex artery (LCx) region included five segments,
and the right coronary artery (RCA) region included
five segments. Two nuclear cardiologists independ-
ently performed visual evaluation of myocardial perfu-
sion imaging. The observers performed image
evaluations blinded to the patients’ clinical informa-
tion and other imaging data. Discordant findings were
resolved by a third observer. A standard five-point
visual scoring system was used for evaluating regional
myocardial MIBI uptake: 0 normal perfusion, 1 mild
reduction, 2 moderate reduction, 3 severe reduction,
and 4 absent uptake [19, 21]. Accelerated MIBI myo-
cardial clearance was defined as an increase of 1 or
more in the segmental defect score at the additional
delayed rest image obtained at the 3-h mark after
MIBI administration as compared with the early rest
image [5]. MIBI redistribution was defined as a de-
crease of 1 or more in the segmental defect score at
the delayed rest image as compared with the early
rest image in segments with reduced uptake at initial
rest imaging [22]. The percentage peak uptake was
also analyzed in each LV segment using the Heart
Function View software (Nihon Medi-Physics Co.,
Ltd., Tokyo, Japan).
Echocardiography
Echocardiography was performed early after reperfusion
therapy and at 6 months after the onset of ACS (Fig. 1).
All echocardiographic examinations were performed by
experienced echocardiographers blinded to the clinical
information, PET image findings, and SPECT image
findings. We used a commercially available ultrasound
system (Sonos 5500, Philips Medical Systems, Andover,
MA, USA) equipped with a broadband harmonic
phased-array transducer (S4 probe). LV wall motion was
evaluated using the 16-segment model based on the ASE
recommendations [20]. LV wall motion was evaluated
using a five-point scoring system according to the ASE
guidelines: 1 normokinesis, 2 mild hypokinesis, 3 severe
hypokinesis, 4 akinesis, and 5 dyskinesis [20]. Six
months after the onset of ACS, we evaluated the re-
gional wall motion as a follow-up study (Fig. 1). A de-
crease of more than 1 in the LV wall motion score at
follow-up compared with the initial study was defined as
regional wall motion improvement [23]. Left ventricular
hypertrophy (LVH) was defined as interventricular septal
wall thickness or posterior wall thickness of 11 mm or
more [20].
11C-acetate positron emission tomography
Patients were instructed to fast for at least 6 h prior to
11C-acetate PET study. Patients were positioned with the
heart centered in the field of view in a whole-body PET
scanner (ECAT HR+, Siemens/CTI Knoxville, TN, USA)
[9, 24]. A dynamic PET acquisition was initiated (10 ×
10, 2 × 30, 5 × 100, 3 × 180, and 2 × 300 s) [10, 25] just
after intravenous administration of 740 MBq of 11C-acet-
ate. Blood pressure, heart rate, and electrocardiography
were monitored during the PET scans.
11C-acetate PET data analysis
PET image data were analyzed using an image analysis
package (Dr. View; Asahi Kasei, Tokyo, Japan) and a spe-
cial dedicated in-house software called the Hokkaido
Quantitative Tool (HOQUTO) [9, 26]. The images were
iteratively reconstructed and resliced along the short axis
[27]. Based on the ASE recommendations [20], regions
of interest were defined for each of the 16 segments.
Regional oxidative metabolism was determined from
the mono-exponential function (kmono) fit to the linear
portion of the semilogarithmic plot. The mono-
exponential fit began at the point where the blood pool
was stable (usually 2 to 4 min after injection) as previ-
ously described [8, 24, 28]. All data were analyzed by nu-
clear cardiologists blinded to clinical information and
other imaging data.
Statistical analysis
Continuous variables were expressed as mean plus
standard deviation. Categorical variables were described
as number and percentage. The Wilcoxon signed-rank
test was performed between the initial and follow-up
echocardiographic measurements. We evaluated the dif-
ference in oxidative metabolism (kmono) among the three
types of segments, namely those in group N, group AC,
and group F, using a linear mixed effects model. Random
effects were defined as subject, and fixed effects were de-
fined as segment type. Then, we analyzed the differences
among the three groups using multi-group comparison.
Logistic regression analysis was performed to analyze
the relationship between the time of ACS onset to reper-
fusion and the presence or absence of accelerated MIBI
clearance. All statistical analyses were performed using R




We enrolled 18 ACS patients who had immediate revas-
cularization for the culprit vessel. No patient had a diag-
nosis of hypertrophic cardiomyopathy. Nine patients
were revascularized for LAD. Two patients were revas-
cularized for the LCx artery and the remaining seven
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patients for the RCA (Table 1). All patients were revas-
cularized using a coronary artery stent and obtained
TIMI flow grade 3 by the end of percutaneous coronary
intervention (PCI). The required time from ACS onset
to revascularization was 5.4 ± 6.8 h. Peak creatine kinase
(CK) level was 1697.6 ± 1522.5 IU/L (range 112–
5056 IU/L, Table 2). One patient had already undergone
PCI for the LAD artery due to angina pectoris prior to
ACS onset. However, this patient’s culprit region at the
ACS event was the RCA. Therefore, we included this pa-
tient in the present study. Detailed information related
to the ACS events of each patient is provided in Table 2.
Echocardiography findings
Initial echocardiography study was performed 7.4 ±
2.8 days after ACS onset (range 2–12 days). LVH was
observed in eight patients based on the ASE guidelines
criteria [20]. At the initial study, group AC (n = 14)
showed higher wall motion scores than group N (n = 64)
(2.29 ± 0.99 vs 1.47 ± 0.62, p < 0.01). Group F also
showed higher wall motion scores than group N (n = 17)
(2.41 ± 1.06 vs 1.47 ± 0.62, p < 0.01).
MIBI SPECT findings
MIBI SPECT was performed 8.9 ± 3.7 days after ACS
onset (range 3–20 days). Accelerated MIBI clearance
was observed in 10 out of 18 patients (56 %). The
time from ACS onset to revascularization was not as-
sociated with the presence or absence of accelerated
MIBI clearance (p = 0.52). There was no significant
correlation between the time from revascularization
to SPECT and numbers of segments (R = 0.23, p =
0.36). In addition, the time from ACS onset to initial
MIBI SPECT imaging was not associated with the
presence or absence of accelerated MIBI clearance (p
= 0.20). Among a total 288 LV segments, we evaluated
99 segments related to revascularized coronary arter-
ies. Four segments showed MIBI redistribution in a
delayed rest image, and these segments were excluded
from the analysis [29]. Among the remaining 95 seg-
ments, 64 were defined as having normal myocardial
perfusion at early and delayed rest images (group N).
Fourteen segments showed accelerated MIBI clearance
(group AC), and 17 segments showed fixed perfusion
defect (group F).
In group AC, the defect score significantly increased at
delayed rest images as compared with early rest images
(p < 0.001) (Table 3). Group N and group F showed simi-
lar defect scores at early and delayed rest images (group
N p = 0.32 and group F p = 0.33) (Table 3). The percent-
age peak uptake was analyzed in 17 patients. Reduction
of percentage peak uptake tended to be higher in group
AC than in group N (Tables 4 and 5).
Regional left ventricular oxidative metabolism
11C-acetate PET was performed 8.8 ± 2.9 days after
ACS onset (range 3–13 days). Group AC showed a
lower oxidative metabolism (kmono) than group N
(0.041 ± 0.009 vs 0.049 ± 0.010, p = 0.02) (Figs. 2 and
3). Group F also showed a lower oxidative metabol-
ism (kmono) than group N (0.039 ± 0.012 vs 0.049 ±
0.010, p = 0.01). However, there was no difference in
oxidative metabolism (kmono) between group AC and
group F (p = 0.99).
Follow-up echocardiography evaluation
At the follow-up (mean follow-up 7.8 ± 4.5 months),
three patients had in-stent restenosis in the reper-
fused coronary artery region as shown through coron-
ary angiography. One patient did not have follow-up
Table 1 Baseline patient characteristics. Data are n, with
percentages in parentheses, or mean ± SD, unless otherwise
indicated
Characteristic All patients (n = 18)
Age, years 69.2 ± 8.7
Male 10 (56 %)
Culprit region
LAD 9 (50 %)
LCx 2 (11 %)
RCA 7 (39 %)
Time from onset to revascularization, h 5.4 ± 6.8
Revascularization method, n (%)
Stent 18 (100 %)
Peak creatine kinase, IU/L 1697.6 ± 1522.5
Coronary risk factor, n (%)
Hypertension 9 (50 %)
Diabetes mellitus 5 (28 %)
Dyslipidemia 10 (56 %)
Smoking history 9 (50 %)
Past history
Pacemaker implantation 1 (6 %)
Post PCI 1 (6 %)
Hemodynamics
Systolic blood pressure, mmHg 122.7 ± 14.9
Diastolic blood pressure, mmHg 62.3 ± 9.9
Heart rate, beats per min 63.3 ± 9.2
Echocardiography data
LVEF, % 56.5 ± 9.5
Interventricular septal wall thickness, mm (range) 10.4 ± 1.9 (7–16)
Posterior wall thickness, mm (range) 9.2 ± 1.1 (7–12)
LAD left anterior descending artery, LCx left circumflex artery, RCA right
coronary artery, PCI percutaneous coronary intervention, LVEF left ventricular
ejection fraction
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echocardiography. Therefore, these four patients were
excluded from the follow-up echocardiographic study,
and we evaluated regional wall motion changes be-
tween the initial and follow-up study in 14 patients.
Among 224 segments in these 14 patients, 74 seg-
ments were related to revascularized coronary arter-
ies, and we evaluated these segments as a follow-up
study. Group N showed improved LV wall motion
score compared with that at its initial study (n = 47)
(1.47 ± 0.62 to 1.25 ± 0.53, p = 0.002) (Fig. 4). Group
AC also showed improved LV wall motion score com-
pared with that at its initial study (n = 10) (2.29 ± 0.99
to 2.00 ± 0.82, p = 0.04). In contrast, the regional wall
motion score in group F did not change compared
with that at its initial evaluation (n = 17) (2.41 ± 1.06
to 2.47 ± 1.12, p = 0.82).
Discussion
Segments with accelerated MIBI clearance were associ-
ated with impaired myocardial oxidative metabolism as
evaluated by 11C-acetate PET in patients with reperfused
ACS. Segments with accelerated MIBI clearance also
showed impaired regional wall motion. LV wall motion
in accelerated MIBI clearance improved at follow-up in
patients with reperfused ACS.
Accelerated MIBI clearance and mitochondrial dysfunction
Approximately 90 % of MIBI accumulates on the mito-
chondrial membrane in relation to its electrical gradient
[3, 30]. In experimental studies, loss of mitochondrial
membrane potential was associated with a decrease in
MIBI uptake [3]. Myocardial cell injury caused acceler-
ated MIBI clearance in ischemic myocardium in a canine
Table 2 Detailed patients’ information about their ACS events





1 RCA No 374 2.4 No
2 LCx Yes 268 NA No
3 RCA No 853 5.0 No
4 RCA No 1550 5.0 Yes
5 LAD Yes 612 NA Yes
6 LAD Yes 4189 5.0 No
7 RCA No 1943 1.5 Yes
8 LAD Yes 1133 4.2 No
9 LAD No 4874 3.0 Yes
10 LAD Yes 5056 3.0 Yes
11 LAD Yes 952 NA Yes
12 LAD No 969 1.0 No
13 RCA Yes 2040 4.0 Yes
14 RCA No 2415 4.5 Yes
15 LCx Yes 112 NA No
16 LAD No 617 3.0 Yes
17 RCA No 1411 28.5 Yes
18 LAD No 1188 6.0 No
Pt patient, LVH left ventricular hypertrophy, RCA right coronary artery, LCx left circumflex artery, LAD left anterior descending artery, CK creatine kinase,
MIBI 99mTc-sestamibi, NA not available
Table 3 MIBI SPECT defect score
Segment numbers Early image Delayed image p value
Group N (n = 64) 0.03 ± 0.12 0.04 ± 0.14 0.32
Group AC (n = 14) 0.75 ± 0.87 1.96 ± 0.89 <0.001
Group F (n = 17) 2.15 ± 0.77 2.18 ± 0.77 0.33
Data expressed as mean ± SD, unless otherwise indicated
MIBI 99mTc-sestamibi, group N segments showed normal perfusion in MIBI
scintigraphy in rest and delayed images, group AC segments showed
accelerated MIBI clearance by increase of one or more in defect score in MIBI
scintigraphy in delayed image, group F segments showed fixed perfusion
defect in MIBI scintigraphy in rest and delayed images
Table 4 MIBI SPECT percentage peak uptake
Segment numbers Early image, % Delayed image, % p value
Group N (n = 61) 71.4 ± 13.0 70.2 ± 12.5 0.047
Group AC (n = 14) 61.1 ± 12.3 57.9 ± 13.0 0.08
Group F (n = 15) 53.7 ± 10.8 48.1 ± 10.7 <0.001
Data expressed as mean ± SD, unless otherwise indicated
MIBI 99mTc-sestamibi, group N segments showed normal perfusion in MIBI
scintigraphy in rest and delayed images, group AC segments showed
accelerated MIBI clearance by increase of 1 or more in defect score in MIBI
scintigraphy in delayed image, group F segments showed fixed perfusion
defect in MIBI scintigraphy in rest and delayed images
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model [31, 32]. In addition, in hypertrophic cardiomyop-
athy, there was an association between accelerated MIBI
clearance and the change of mitochondrial structure as
observed in histological examinations [16, 33]. Hayashi
et al. reported that accelerated MIBI clearance was cor-
related with the severity of degeneration in the mito-
chondria in dilated cardiomyopathy [16]. In the current
study, segments with accelerated MIBI clearance showed
decreased myocardial oxidative metabolism in patients
with ACS. Therefore, reduced oxidative metabolism may
reflect mitochondrial dysfunction in ischemic myocar-
dium as well as in either hypertrophic or dilated cardio-
myopathy. These data appear to corroborate those from
previous experimental studies, and the current data may
therefore clarify the possible mechanisms of accelerated
MIBI clearance in patients with ACS.
In the current study, accelerated MIBI clearance was
observed in ten patients (55 %), and segmental analysis
showed that 14 of the 99 segments (14 %) exhibited ac-
celerated MIBI clearance. Takeishi et al. reported that 15
of the 22 patients (68 %) with acute myocardial infarc-
tion showed accelerated MIBI clearance [5]. In their
study, these patients had percutaneous transmural cor-
onary angioplasty and thrombolytic therapy. The fre-
quency of accelerated MIBI in the current study was
lower than in Takeishi’s study. In their study, all patients
who underwent angioplasty obtained TIMI grades 2 or 3
by the end of the revascularization procedure. The dif-
ference in the frequency of accelerated MIBI between
the current study and Takeishi’s study may be due to dif-
ferences in coronary intervention approach. In the
current study, all patients underwent stent placement as
the ACS treatment. In addition, all patients had obtained
TIMI grade 3 by the end of the revascularization pro-
cedure. Given recent developments in treatment ap-
proaches, ACS treatments may have improved in
comparison with those used in previous studies. There-
fore, newer revascularization approaches may result in
less myocardial damage and a lower frequency of accel-
erated MIBI clearance. Even with the lower frequency of
accelerated MIBI clearance, the main finding of the
current study agreed with the findings from the previous
study, and the current study adds new pathophysio-
logical insights over the previous study.
Fujiwara et al. reported that the regions of accelerated
MIBI clearance were closely correlated with those show-
ing reduced uptake of 123iodine-beta-methyl-iodophenyl-
pentadecanoic acid (BMIPP) [34]. BMIPP defect is asso-
ciated with abnormal myocardial fatty acid metabolism
[35]. Their data indicate that accelerated MIBI clearance
may be associated with myocardial metabolic dysfunc-
tion in ACS. Although they did not evaluate oxidative
metabolism, their data may support the current findings.
In the current study, reduction of percentage peak up-
take in the segments of accelerated sestamibi clearance
showed a trend of being higher than that in normal per-
fusion segments. However, this was not significant. Since
tracer decay might have impacts on the percentage peak
uptake, this may have had an influence on the relative
uptake analysis.
Accelerated MIBI clearance and wall motion recovery
The regions with accelerated MIBI clearance showed LV
wall motion improvement at follow-up after revasculari-
zation. Using low-dose dobutamine stress echocardiog-
raphy, Fujiwara et al. evaluated the association between
accelerated MIBI clearance and regional wall motion
after ACS (within 7 days of admission) [6]. Segments
with accelerated MIBI clearance showed better func-
tional recovery during low-dose dobutamine administra-
tion than those with fixed MIBI defects. Their study
revealed accelerated MIBI clearance associated with dys-
functional but viable myocardium early after ACS. The
current study further added to the new insight that ac-
celerated MIBI clearance in segments was related to re-
gional wall motion recovery at follow-up. Thus, the
current study provided insights into the association be-
tween accelerated MIBI clearance and regional LV func-
tional recovery in addition to those provided by previous
studies [5, 6].
Table 5 Percent change of percentage peak uptake
Segment numbers Percent change of
percentage peak uptake
Group N (n = 61) −1.2 ± 5.4
Group AC (n = 14) −3.2 ± 5.9
Group F (n = 15) −5.6 ± 4.2*





























Fig. 2 Oxidative metabolism (kmono) in each segment among the
three groups
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Myocardial oxidative metabolism in the segments
with accelerated MIBI clearance decreased as the
number of segments with fixed perfusion abnormality
did. Segments with accelerated MIBI clearance
showed improved LV wall motion. However, the LV
wall motion in segments with fixed perfusion abnor-
mality remained unchanged at follow-up. Thus, based
on the current findings, it may be difficult to predict
regional wall motion recovery using 11C-acetate PET
data. The effectiveness of 11C-acetate PET to predict
myocardial functional recovery has not been fully rec-
ognized [36–40]. Hicks et al. reported that oxidative
metabolism did not depend on myocardial perfusion.
They also reported that oxidative metabolism varied
in accordance with myocardial conditions such as is-
chemia or infarction [37]. They concluded that pre-
dicting functional recovery through the evaluation of
oxidative metabolism alone was difficult. Our results
suggest that segments with impaired oxidative metab-

















Fig. 3 Representative case of an 85-year-old man who underwent emergent PCI for LAD. 99mTc-sestamibi (MIBI) scintigraphy and 11C-acetate PET
were performed 10 days after PCI. a Early and delayed images of MIBI SPECT. Accelerated MIBI clearance is observed in the anterior region. b Polar
maps of MIBI in early (upper) and delayed (lower) images. c Oxidative metabolism (kmono) in each segment. d
11C-acetate PET time-activity curve
at the mid-anterior wall. Mid-anterior wall exhibited accelerated MIBI clearance in MIBI scintigraphy. e 11C-acetate PET time-activity curve at the
basal-anterior wall. Basal-anterior wall showed normal perfusion in rest and delayed images in MIBI scintigraphy. PCI percutaneous coronary intervention,










































Fig. 4 Changes in echocardiographic regional LV wall motion score between initial study and follow-up study
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However, this finding was not sufficient to predict
myocardial functional recovery based on the current
data. Therefore, further studies are required.
Clinical indication
Evaluation of accelerated MIBI clearance may provide
additional information in a clinical setting. Our study
may indicate that segments with accelerated MIBI clear-
ance represent myocardium damage as a result of mito-
chondrial dysfunction.
Limitations
Our study had some limitations. First, histological find-
ings for the regions showing accelerated MIBI clearance
were not evaluated. Rather than performing biopsy sam-
pling, we evaluated myocardial oxidative metabolism as
a marker of mitochondrial dysfunction using 11C-acetate
PET. In experimental studies, the clearance of 11C-acet-
ate from myocardium is associated with mitochondrial
function [15]. Therefore, the current data support our
hypothesis. Second, myocardial oxidative metabolism
was not evaluated at follow-up. A previous study re-
ported an improvement in oxidative metabolism in the
reperfused myocardium [37]. Examining this information
with regard to physiological changes to ACS after reper-
fusion therapy might be an important next step. Third,
for evaluation purposes, we did not separate patients
with ACS into groups based on the following patho-
logical conditions: unstable angina, NSTEMI, and
STEMI. These three types of pathological conditions
may exhibit related pathology in terms of myocardial
damage. Finally, our study involved a small study popu-
lation. The current protocol included two sestamibi
SPECT data acquisitions, echocardiography, and one
11C-acetate PET study. 11C-acetate PET is usually ap-
plied for specific pathophysiological studies in a limited
number of research facilities [25, 41], and it would be
difficult to apply this comprehensive study protocol to a
large number of subjects. In addition, the sample size of
the present study was small but similar to that of previ-
ous studies [39, 41, 42]. Despite the small sample size,
with careful preparation, we showed the pathophysio-
logical mechanism of accelerated sestamibi washout.
While a small sample size may have had a minimal im-
pact on the current data, we definitely need further
study using a larger study population to confirm the effi-
cacy of evaluating MIBI clearance. The time from revas-
cularization to SPECT showed some variability.
However, there was no significant correlation between
the time from revascularization to SPECT and the num-
bers of accelerated sestamibi clearance segments. There-
fore, time from revascularization to SPECT might not
have had an impact on the numbers of segments with
accelerated sestamibi clearance.
Conclusions
Segments with accelerated MIBI clearance were associ-
ated with impaired myocardial oxidative metabolism as
evaluated by 11C-acetate PET. Segments with accelerated
MIBI clearance showed impaired regional wall motion.
Accelerated MIBI clearance may be associated with
mitochondrial dysfunction and might be a predictor of
LV wall motion improvement in patients with ACS who
underwent immediate revascularization therapy.
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